Laigo Bio

About Laigo Bio

Laigo Bio is a biotechnology company pioneering protein degradation for targeted therapies. They focus on eradicating disease-causing targets, including those previously considered undruggable, using their proprietary SureTAC platform to develop innovative treatments and forge a path toward a healthier tomorrow.

Products & Services

SureTACs (Surface Removal Targeting Chimeras):A novel technology using bispecific antibodies to facilitate precise removal of cell surface proteins via ubiquitin-mediated degradation. It targets undruggable proteins, offers deeper pathway inhibition, and provides tissue-specific action, initially focusing on oncology with expansion into immunology and neuroinflammation.

SureTACs™ (Surface Removal Targeting-Chimeras)

Specialties

Protein Degradation Targeted Therapies Bispecific Antibodies Oncology Immunology Neuroinflammation E3 Ligase Research Targeted protein degradation Bispecific antibodies E3 ligase biology Auto-immunity

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 18360000 MR: - FA: €17 million FAN: 18360000	D: 2026-03-23 FD: 2026-03-23	9 investors
2	RT: Seed T: - FT: Seed	A: 12650000 MR: - FA: €11.5 million FAN: 12650000	D: 2025-12-04 FD: 2025-12-04	8 investors

Seed Latest

2026-03-23

$18.4M

9 investors (Pro only)

Seed 2025-12-04

$12.7M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

Laigo Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised